

Immuno-Resistance and Sequencing Symposium

Thursday, Nov. 11, 2021

7:30 a.m.–6 p.m. EST

Session I: Novel Primary vs. Adaptive Resistance Mechanisms

Time: 7:30–9:15 a.m.

Moderator: Ira Mellman, PhD – *Genentech, Inc.*

7:30 a.m. **Introduction**
Samir N. Khleif, MD – *Georgetown University Medical Center*

7:35 a.m. **Anti-PD1 Resistance – Different Flavors**
Samir N. Khleif, MD – *Georgetown University Medical Center*

7:55 a.m. **Dissecting the Complexity of HLA Loss in Cancer**
Christian Hammer, PhD – *Genentech, Inc.*

8:15 a.m. **Dissecting Evolution of Clinical Immunotherapy Resistance**
David Liu, MD, MPH, MS – *Dana-Farber Cancer Institute*

8:35 a.m. **Immune Checkpoint Therapy: Identification of Resistance Mechanisms**
Padmanee Sharma, MD, PhD – *The University of Texas MD Anderson Cancer Center*

8:55 a.m. **Session I Panel Discussion**
Moderator: Ira Mellman, PhD – *Genentech, Inc.*
Panelists: Session I Speakers
Michael B. Atkins, MD – *Georgetown Lombardi Comprehensive Cancer Center*

9:15 a.m. **Break**

Session II: Myths vs. Knowledge on Clinical Therapeutic Mechanisms – Lessons Learned

Time: 9:30–11:10 a.m.

- Moderator:** Andrew D. Weinberg, PhD – *Earle A. Chiles Research Institute, Providence Portland Medical Center*
- 9:30 a.m. **Single Agent Trials, Lessons Learned - OX40 Agonists are Still Alive**
Andrew D. Weinberg, PhD – *Earle A. Chiles Research Institute, Providence Portland Medical Center*
- 9:50 a.m. **Role of Tim3 in Myeloid Cells**
Vijay K. Kuchroo, DVM, PhD – *Center for Neurologic Diseases, BWH*
- 10:10 a.m. **Anti-PD1 and IDO1 Inhibition: Lessons Learned**
Lance Leopold, MD – *Incyte*
- 10:30 a.m. **Priming the Immune System to Provoke Checkpoints: The Path to Maintaining the Immunotherapy Momentum**
Elizabeth M. Jaffee, MD – *Sidney Kimmel Cancer Center, Johns Hopkins University*
- 10:50 a.m. **Session II Panel Discussion**
Moderator: Andrew D. Weinberg, PhD – *Earle A. Chiles Research Institute, Providence Portland Medical Center*
Panelists: Session II Speakers

Session III: Understanding the Biology of Therapeutic Pillars – Targeted Pathways and Future Direction

- Time:** 11:10 a.m.–2:20 p.m.
- Moderator:** E. John Wherry, PhD – *University of Pennsylvania*
- 11:10 a.m. **VISTA Targeting of T cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance**
J. Louise Lines, PhD – *Dartmouth College*
- 11:30 a.m. **Human Costimulatory Bispecific Antibodies in Cancer Immunotherapy**
Dimitros Skokos, PhD – *Regeneron Pharmaceuticals, Inc.*
- 11:50 a.m. **Lunch Break**
- 1:20 p.m. **In Pre-clinical Models Metabolic Manipulations Improve the Efficacy of T cell Immunotherapy of Melanoma**
Hildegund Ertl, MD – *The Wistar Institute*
- 1:40 p.m. **Molecular Mechanisms of T cell Exhaustion and Relevance for Immunotherapy of Cancer**
E. John Wherry, PhD – *University of Pennsylvania*

2:00 p.m.

Session III Panel Discussion

Moderator: E. John Wherry, PhD - *University of Pennsylvania*

Panelists: Session III Speakers

Session IV: Resistance Reversal Strategies & Sequencing

Time: 2:20–4:20 p.m.

Moderator: Samir N. Khleif, MD – *Georgetown University Medical Center*

2:20 p.m.

Cellular Mechanisms of Cancer Immunity Response and Resistance

Ira Mellman, PhD – *Genentech, Inc.*

2:40 p.m.

T cell Activation and Timing

Benjamin Youngblood, PhD - *St. Jude Children's Research Hospital*

3 p.m.

Mapping Immunosuppressive Cell in the Tumor Microenvironment

Miriam Merad, MD, PhD – *Icahn School of Medicine at Mount Sinai*

3:20 p.m.

Machine Learning for Spatial Multi-omics in Cancer Immunotherapy

Elana Fertig, PhD - *Johns Hopkins University*

3:40 p.m.

Autophagy and Immunometabolism Regulation of CD8+ T cell Antitumor Immunity

Julian J. Lum, PhD – *BC Cancer*

4 p.m.

Session IV Panel Discussion – Rational Combination Design

Moderator: Samir N. Khleif, MD – *Georgetown University Medical Center*

Panelists: Session IV Speakers

4:20 p.m.

Break

Session V: Developmental Process

Time: 4:35–6 p.m. EST

Moderator: Kald Abdallah, MD, PhD - *Bristol Myers Squibb*

4:35 p.m.

Novel Immunotherapy Clinical Trial Design

Osama E. Rahma, MD – *AstraZeneca*

- 4:55 p.m. **Combinations of Agents without Single-agent Activity**
Kald Abdallah, MD, PhD – *Bristol Myers Squibb*
- 5:15 p.m. **Regulatory Considerations for Cancer Immunotherapeutic Development – anti-PD-(L)1 resistance**
Marc Theoret, MD – *Food and Drug Administration (FDA)*
- 5:35 p.m. **Session V Panel Discussion**
Moderator: Kald Abdallah, MD, PhD - *Bristol Myers Squibb*
Panelists: Session V Speakers
- 5:55 p.m. **Closing Remarks**
Samir N. Khleif, MD – *Georgetown University Medical Center*